Lung transplant rejection - Pipeline Insight, 2024

Lung transplant rejection - Pipeline Insight, 2024

DelveInsight’s, “Lung transplant rejection - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lung transplant rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lung transplant rejection Understanding

Lung transplant rejection: Overview

Lung transplant rejection is a common complication after a single or double lung transplant, and it can progress rapidly or subtly. Early diagnosis and management are essential to decrease morbidity and mortality. It is best managed by an interprofessional team approach. Communication and coordination between the patient, the primary clinician, the pulmonologist, and the transplant surgeon in regard to posttransplant testing and follow-up are essential for prevention. Acute lung transplant rejection may increase the risk of a recurrence of acute rejections and the development of bronchiolitis obliterans syndrome.

""Lung transplant rejection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lung transplant rejection pipeline landscape is provided which includes the disease overview and Lung transplant rejection treatment guidelines. The assessment part of the report embraces, in depth Lung transplant rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lung transplant rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Lung transplant rejection R&D. The therapies under development are focused on novel approaches to treat/improve Lung transplant rejection.

Lung transplant rejection Emerging Drugs Chapters

This segment of the Lung transplant rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lung transplant rejection Emerging Drugs

• TFF TAC-LAC: TFF PHARMACEUTICALS

TFF TAC-LAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine. Tacrolimus is currently the second most commonly administered immunosuppressive drug used in solid organ transplants, despite many challenges for patients and physicians when used for extended periods. Tacrolimus can cause toxicity in the kidneys, particularly when used in high doses. TFF TAC-LAC is a dry powder version suitable for use with a dry powder inhaler. This provides for a high local lung concentration without the problems of an orally dosed tacrolimus.

• Belatacept: Bristol-Myers Squibb

Belatacept is a CTLA4-Ig fusion protein that binds CD80 and CD86 thereby blocking CD28 co-stimulatory signals. Belatacept is a second-generation fusion protein developed by Bristol-Myers Squibb for the prevention of renal and lung transplant rejection.

Further product details are provided in the report……..

Lung transplant rejection: Therapeutic Assessment

This segment of the report provides insights about the different Lung transplant rejection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Lung transplant rejection

There are approx. 7+ key companies which are developing the therapies for Lung transplant rejection. The companies which have their Lung transplant rejection drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.

• Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Lung transplant rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lung transplant rejection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lung transplant rejection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lung transplant rejection drugs.

Lung transplant rejection Report Insights

• Lung transplant rejection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lung transplant rejection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lung transplant rejection drugs?
• How many Lung transplant rejection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lung transplant rejection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lung transplant rejection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lung transplant rejection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• TFF Pharmaceuticals
• Bristol-Myers Squibb
• Zambon SpA
• CSL Behring
• MimeTech
• Roche
• Corline Biomedical
• Kamada
• Quark Pharmaceuticals
• Radikal Therapeutics

Key Products

• TFF TAC-LAC
• Belatacept
• Liposomal Cyclosporine A
• Hizentra
• Udonitrectag
• Pirfenidone
• Renaparin
• Alpha-1 antitrypsin
• QP LI1